Ligufalimab and Cadonilimab in Advanced Liver Cancers

The goal of this clinical trial is to find out if the combination of Ligufalimab and Cadonilimab are effective in treating advanced hepatobiliary cancers that have failed prior therapy.

Trial Details

NCT ID
NCT06789848
Phase
PHASE2
Sponsor
University of Texas Southwestern Medical Center
Status
RECRUITING
Cancer Type
Cholangiocarcinoma (Bile Duct) Liver Cancer
Interventions
  • Ligufalimab
  • Cadonilimab
Locations (sample)
  • Dallas, Texas, United States|32.78306,-96.80667

Key Eligibility Criteria

  • Histological confirmation of specific disease -Cohort A (HCC): Patient must have a diagnosis confirmed by histology or clinically by the American A…
  • Cohort B (BTC, biliary tract cancers): Patients must have histologically confirmed biliary tract cancer (including intrahepatic cholangiocarcinoma,…
  • Locally advanced or metastatic disease
  • Patients with locally advanced or metastatic disease must have disease deemed not amenable to surgical and/or locoregional therapies or patients wh…

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Cholangiocarcinoma (Bile Duct) Liver Cancer Trials on Trialify →